Biocartis provides the Idylla™ platform, a fully automated real‑time PCR system that delivers comprehensive oncology biomarker results in about three hours. The solution integrates sample preparation, nucleic acid extraction, amplification and detection in a single disposable cartridge, requiring minimal hands‑on time and only a small tissue or plasma sample, making fast, accurate molecular testing accessible to any pathology or diagnostic laboratory.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinical molecular testing for cancer biomarkers often requires bulky equipment, lengthy turnaround times, and extensive hands‑on preparation, limiting timely treatment decisions and restricting implementation to large, specialized laboratories.
Solution
Biocartis offers the Idylla™ platform, a fully automated real‑time PCR system that delivers comprehensive oncology biomarker results in approximately three hours. The system integrates sample preparation, nucleic acid extraction, amplification, and detection within a single disposable cartridge, eliminating the need for multiple instruments and extensive consumables. Minimal sample input (one tissue slice or 1 mL of plasma) enables testing even when specimen volume is limited. Results are presented in a clear, standardized report that can be used alongside next‑generation sequencing workflows, accelerating clinical decision‑making. The platform is designed for easy integration into any laboratory setting, requiring little training and reducing hands‑on time to a few minutes.
Target Audience
Primary customers are pathology laboratories and oncology clinics that need fast, reliable molecular biomarker testing, as well as hospital and diagnostic labs seeking a compact, automated solution for cancer precision medicine.
Features
- Fully automated workflow from sample to result within ~3 hours
- Single-use cartridge containing all reagents, supporting up to 30 molecular targets per assay
- Real‑time PCR technology with high accuracy, reproducibility, and low invalid rates
- Minimal sample requirement (1 tissue slice or 1 mL plasma) suitable for scarce specimens
- Compatibility with existing lab information systems and easy reporting format
- Designed for any lab size; no need for large equipment or extensive consumable inventory
- Can be used in parallel with NGS for rapid triage of key biomarkers